Syk Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S4944	Fostamatinib disodium hexahydrate	Fostamatinib (R788) disodium (Tamatinib Fosdium) hexahydrate, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM in a cell-free assay.	Int J Hematol, 2022, 10.1007/s12185-021-03220-9 J Allergy Clin Immunol, 2021, S0091-6749(21)00979-9 ScholarsArchive@OSU, 2020, None
S9715	Lanraplenib (GS-SYK)	Lanraplenib (GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. It inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.	Cell Rep, 2024, 43(10):114773 Blood Adv, 2024, bloodadvances.2024014167 bioRxiv, 2024, 2024.09.26.615160
S7286	RO9021	RO9021 potently inhibits SYK kinase activity with an average IC50 of 5.6 nM and suppresses B-cell receptor signaling.	Microbiol Spectr, 2025, 13(1):e0254921 Int J Mol Sci, 2022, 23(23)14706
S6519	R112	R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor with Ki value of 96 nM.
E1836	Cevidoplenib dimesylate	Cevidoplenib dimesylate(SKI-O-703 dimesylate) is an orally available inhibitor of spleen tyrosine kinase (Syk) with potential anti-inflammatory and immunomodulating activities. It attenuates the progression of autoantibody-mediated autoimmune diseases by inhibiting both autoantibody-producing and autoantibody-sensing cells.
S0871	Gusacitinib (ASN-002)	Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
S8948	SRX3207	SRX3207 is an orally active dual inhibitor of Syk-PI3K with IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM for Syk, Zap70, BRD41, BRD42, PI3K alpha, PI3K delta, PI3K gamma, respectively. This compound blocks tumor immunosuppression and increases anti-tumor immunity.
E0437	ZAP-180013	ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM.
E7793	PRT062607	PRT062607 is a highly specific, potent and orally bioavailable inhibitor of purified Spleen tyrosine kinase (SYK) with an IC50 of 1-2 nM. It exhibits significant anti-inflammatory activity and can be used in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis research.
E4580	Sovleplenib	Sovleplenib (HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. This compound exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).
S7634	Cerdulatinib (PRT062070) hydrochloride	Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.	Antimicrob Agents Chemother, 2024, 68(4):e0135023. Int J Mol Sci, 2023, 24(17)13623 Cells, 2023, 12(3)453
S3566	Cerdulatinib (PRT062070)	Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively, also inhibits19 other tested kinases with IC50 less than 200 nM.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Methods, 2025, 241:13-23 NPJ Precis Oncol, 2024, 8(1):74
S4921	MNS (3,4-Methylenedioxy-β-nitrostyrene)	MNS (3,4-Methylenedioxy-β-nitrostyrene) is a tyrosine kinase inhibitor that inhibits Syk, Src, and p97 with IC50 values of 2.5 μM, 29.3 μM, and 1.7 μM, respectively.	Journal of Biomedical Engineering, 2021, 38(5):903-910 Phytomedicine, 2019, 61:152859 J Biomol Struct Dyn, 2019, 10.1080/07391102.2019.1640133
S3226	Dehydroabietic acid	Dehydroabietic acid (DAA, DHAA), a naturally occurring diterpene resin acid derived from coniferous plants such as Pinus and Picea, displays anti-inflammatory activity via suppression of Src-, Syk-, and TAK1-mediated pathways.